Howard Berman, PhD, is an accomplished leader in the biotechnology and pharmaceutical industries, currently serving as a Member of the Board of Directors at Esya Labs, which focuses on developing multiplex blood diagnostic assays for neurodegenerative diseases. As the Founder and Chief Executive Officer of Coya Therapeutics, Inc., Howard is pioneering transformative approaches in targeting regulatory T cell biology. Previously, Howard founded imaware™, a digital health platform that has significantly impacted early disease detection through remote testing protocols. Howard's extensive experience includes key roles at AbbVie and Eli Lilly and Company, where responsibilities encompassed medical affairs, business development, and strategic initiatives for numerous cancer therapeutics. Early in their career, Howard worked at Novartis and MD Anderson Cancer Center, focusing on clinical trial collaborations and technology transfer in oncology. Howard holds a PhD in Pharmacology and brain imaging from Joan & Sanford I. Weill Medical College of Cornell University and a Bachelor's degree in Biological Sciences from the University of Michigan.
This person is not in the org chart
This person is not in any teams
This person is not in any offices